Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Chief Executive Officer Dr Howie McKibbon will present to institutional investors at today’s Canaccord Drug and Device Healthcare Conference in Noosa. For the balance of the week, Canaccord Genuity will host a Botanix investor roadshow.
The Quarterly Activity Report and 4C Quarterly Cash Flow Report for Q1 FY2026 have been released. Quarter over quarter, total prescriptions for Sofdra® (sofpironium) increased 50% to 20,418 as operating cash outflow decreased 54% to $13.1 million. Net revenue was $7.1 million.
Join our executive team for the Company’s Quarterly Activity Report and 4C Quarterly Cash Flow Report Webinar on Monday 20 October at 11.00 am AEDT / 8.00 am AWST for an important update.
Botanix Executive Chairman Vince Ippolito will be a featured presenter on Tuesday, 9 September at the HC Wainwright 27th Annual Global Investment Conference in New York, NY (US). This conference attracts institutional fund managers from around the world and some of the most promising global growth companies, including those in the healthcare and life sciences sectors.
https://botanixpharma.com/wp-content/uploads/HC-Wainwright.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2025-09-08 00:41:182025-09-08 00:41:18Botanix featured at global investor conference
Botanix announced that Dongwha Pharm. Co., Ltd. has received regulatory approval for ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea. Dongwha is a sublicensee of Botanix’s Japanese partner, Kaken Pharmaceutical Co. Ltd.
Dongwha – Korea’s first and oldest pharmaceutical company – will commercialise ECCLOCK in the Korean market and add the product to its extensive range of prescription and over-the-counter products.
https://botanixpharma.com/wp-content/uploads/Korea.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2025-09-04 23:31:542025-09-12 22:38:16Botanix announces regulatory approval of ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea
The Annual Report for FY2025 has been released. At year end, Botanix held $64.9 million cash and $15.3 million in undrawn debt. Operating costs are stable with no inventory purchases anticipated in 1H FY2026, and revenue is expected to increase quarterly. The Company is well funded to achieve profitability.
Botanix Presents at Canaccord Conference
/in ASX Releases, Featured, Latest News, News /by Haley ChartresChief Executive Officer Dr Howie McKibbon will present to institutional investors at today’s Canaccord Drug and Device Healthcare Conference in Noosa. For the balance of the week, Canaccord Genuity will host a Botanix investor roadshow.
View ASX Release
Botanix Releases Quarterly Reports
/in ASX Releases, Featured, Latest News, News /by Haley ChartresThe Quarterly Activity Report and 4C Quarterly Cash Flow Report for Q1 FY2026 have been released. Quarter over quarter, total prescriptions for Sofdra® (sofpironium) increased 50% to 20,418 as operating cash outflow decreased 54% to $13.1 million. Net revenue was $7.1 million.
Click to view the Reports.
Quarterly Update Webinar October 20 | Registration Open
/in Featured, Latest News, News /by Haley ChartresJoin our executive team for the Company’s Quarterly Activity Report and 4C Quarterly Cash Flow Report Webinar on Monday 20 October at 11.00 am AEDT / 8.00 am AWST for an important update.
Participants must pre-register: Click here
Botanix featured at global investor conference
/in Featured, Latest News, News, Presentations /by Haley ChartresBotanix Executive Chairman Vince Ippolito will be a featured presenter on Tuesday, 9 September at the HC Wainwright 27th Annual Global Investment Conference in New York, NY (US). This conference attracts institutional fund managers from around the world and some of the most promising global growth companies, including those in the healthcare and life sciences sectors.
View ASX Release & Presentation.
Botanix announces regulatory approval of ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix announced that Dongwha Pharm. Co., Ltd. has received regulatory approval for ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea. Dongwha is a sublicensee of Botanix’s Japanese partner, Kaken Pharmaceutical Co. Ltd.
Dongwha – Korea’s first and oldest pharmaceutical company – will commercialise ECCLOCK in the Korean market and add the product to its extensive range of prescription and over-the-counter products.
Botanix Releases Annual Report
/in ASX Releases, Featured, Latest News, News /by Haley ChartresThe Annual Report for FY2025 has been released. At year end, Botanix held $64.9 million cash and $15.3 million in undrawn debt. Operating costs are stable with no inventory purchases anticipated in 1H FY2026, and revenue is expected to increase quarterly. The Company is well funded to achieve profitability.
View Report.